COMMUNIQUÉS West-GlobeNewswire

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
22/06/2026
The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and [...]
CureWise Founder and CEO Steve Brown to Speak at Aspen Ideas: Health 2026 and Launch AI-Powered Precision Oncology Platform
22/06/2026
CureWise Helps Cancer Patients Understand Their Disease, Explore Personalized Treatment Possibilities, and Advocate for More Targeted Care LOS ANGELES, June 22, 2026 (GLOBE NEWSWIRE) -- In a world where 200 million [...]
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
22/06/2026
D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies. NRx Pharmaceuticals is [...]
GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage
22/06/2026
AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " [...]
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
22/06/2026
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as a DLL3 biomarker- [...]
Clariane has launched a proposed offering of €333 million of undated deeply subordinated hybrid notes to refinance its ODIRNANE
22/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Clariane annonce le lancement d’une offre de 333 millions d’euros d’obligations hybrides à durée indéterminée subordonnées de dernier rang en vue du refinancement de ses ODIRNANE
22/06/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
22/06/2026
COPENHAGEN, Denmark, June 22, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
22/06/2026
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches late-stage development [...]
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
22/06/2026
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026 . Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, Global Head of Research [...]
Communiqué de presse : Sanofi nomme Paulo Fontoura à la tête de sa R&D
22/06/2026
Sanofi nomme Paulo Fontoura à la tête de sa R&D Paris , 22 juin 2026. Sanofi annonce la nomination du Dr Paulo Fontoura au poste de Vice-Président Exécutif, Responsable mondial de la Recherche & Développement [...]
CARBIOS presents the results of its Annual General Meeting of June 18, 2026
22/06/2026
Clermont-Ferrand (France), June 22, 2026 (7:45 am CEST). CARBIOS , (Euronext Growth Paris: ALCRB), announces the results of its Annual Ordinary and Extraordinary General Meeting held on June 18, 2026. Shareholders [...]
CARBIOS présente les résultats de son Assemblée Générale du 18 juin 2026
22/06/2026
Clermont-Ferrand (France), le 22 juin 2026 (7h45 CEST). CARBIOS, (Euronext Growth Paris : ALCRB) annonce les résultats de son Assemblée Générale Ordinaire Annuelle et Extraordinaire du 18 juin 2026. Les actionnaires [...]
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
22/06/2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
SKG Brings Deep Recovery Technology to Father’s Day Gifting
22/06/2026
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- This Father’s Day, SKG is bringing smart recovery to the top of the gift list with wearable smart massagers designed for dads’ everyday routines. As thoughtful gift options, [...]
Automatisation et interopérabilité de la pharmacie hospitalière : Deenova déploiera une plateforme intégrée de gestion du médicament au Policlinico di Milano
22/06/2026
Milan, 22 juin 2026 (GLOBE NEWSWIRE) -- Deenova annonce le lancement des activités pour la réalisation du nouveau système intégré d’automatisation et de traçabilité de la gestion des médicaments au sein de la Fondazione [...]
Pharmacy automation interoperability: Deenova to deliver an integrated medication management platform at Policlinico di Milano
22/06/2026
MILAN, June 22, 2026 (GLOBE NEWSWIRE) -- Deenova announces the launch of activities for the implementation of a new integrated system for the automation and traceability of medication management at Fondazione IRCCS Ca’ [...]
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
21/06/2026
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with [...]
JellyFil Publishes Updated 2026 Product Information for Its Premium Gummy Dietary Supplement, Including Full Ingredient List, Pricing, Refund Policy, and Customer Service Details
20/06/2026
Florida-distributed gummy supplement brand details current ingredients, pricing, refund policy, and customer service processes for 2026 Largo, FL, June 20, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]

Pages